3 results
Not approvedWill not start
The objectives of this study are to demonstrate that Nepafenac Ophthalmic Suspension, 0.3% is not inferior to Nepafenac Ophthalmic Suspension, 0.1% (NEVANAC®); Nepafenac Ophthalmic Suspension, 0.3% is superior to Nepafenac 0.3% Vehicle and NEVANAC…
Approved WMOCompleted
Comparison of adenosine infusion and bolus injection of regadenoson for induction of maximum coronary hyperemia.
Approved WMOCompleted
Main objective: To assess the effect of CK-2127107 versus placebo on respiratory function in patients with ALS.